Articles

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Kindai University Hospital, Osaka-Sayama
Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul
Tokai University Hospital, Isehara
National Hospital Organization Kyushu Cancer Center, Fukuoka
National Cancer Center Hospital, Tokyo
Gunma University Hospital, Maebashi
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo
International Medical Center, Saitama Medical University, Saitama
Kyoto Prefectural University of Medicine, Kyoto
Juntendo University Hospital, Tokyo
National Hospital Organization Kumamoto Medical Center, Kumamoto
Seoul National University Hospital, Seoul
Osaka University Hospital, Suita
Japanese Red Cross Nagoya Daini Hospital, Nagoya
Chonnam National University Hwasun Hospital, Jeollanam
Kagoshima University Hospital, Kagoshima
Yamagata University Hospital, Yamagata
Yonsei University College of Medicine, Severance Hospital, Seoul
Konkuk University Medical Center, Seoul
Kobe University Graduate School of Medicine and Hospital, Kobe
National Cancer Center, Gyeonggi
National Hospital Organization Hokkaido Cancer Center, Sapporo
Gachon University Gil Medical Center, Incheon
Seoul National University Bundang Hospital, Gyeonggi
Inje University Busan Paik Hospital, Busan
National Hospital Organization Nagoya Medical Center, Nagoya
Kyoto University Hospital, Kyoto
Asan Medical Center, University of Ulsan College of Medicine, Seoul
National Hospital Organization Nagasaki Medical Center, Omura
HUYABIO International, San Diego, CA
Huya Japan GK, Tokyo
National Cancer Center Hospital, Tokyo
Haematologica Early view Oct 6, 2022 https://doi.org/10.3324/haematol.2022.280996